Based on the Aptorum Group Ltd Class A stock forecast from 0 analysts, the average analyst target price for Aptorum Group Ltd Class A is not available over the next 12 months. Aptorum Group Ltd Class A’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aptorum Group Ltd Class A is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Aptorum Group Ltd Class A’s stock price was USD 1.20. Aptorum Group Ltd Class A’s stock price has changed by +9.09% over the past week, -43.93% over the past month and -21.57% over the last year.
No recent analyst target price found for Aptorum Group Ltd Class A
No recent average analyst rating found for Aptorum Group Ltd Class A
Company Overview Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Read Less
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the The...Read More
Frequently Asked Questions About Aptorum Group Ltd Class A (APM) Stock
Stock Target Advisor's fundamental analysis for Aptorum Group Ltd Class A's stock is Slightly Bearish.
Unfortunately we do not have enough data on APM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on APM's stock to indicate what its average analyst target is.
APM stock's Price/Earning ratio is 4.48.
Our analysis grades APM stock's Price / Earning ratio at F. This means that APM stock's Price/Earning ratio is above 46% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this APM may be fairly valued for its sector
The last closing price of APM's stock was USD 1.20.
The most recent market capitalization for APM is USD 9.93M.
Unfortunately we do not have enough analyst data on APM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aptorum Group Ltd Class A's stock.
As per our most recent records Aptorum Group Ltd Class A has 3 Employees.
Aptorum Group Ltd Class A's registered address is 17 Hanover Square, London, United Kingdom, W1S 1BN.
You can get more information about it from Aptorum Group Ltd Class A's website at https://www.aptorumgroup.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Aptorum Group Ltd Class A (APM) Stock
Stock Target Advisor's fundamental analysis for Aptorum Group Ltd Class A's stock is Slightly Bearish.
Unfortunately we do not have enough data on APM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on APM's stock to indicate what its average analyst target is.
APM stock's Price/Earning ratio is 4.48.
Our analysis grades APM stock's Price / Earning ratio at F. This means that APM stock's Price/Earning ratio is above 46% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this APM may be fairly valued for its sector
The last closing price of APM's stock was USD 1.20.
The most recent market capitalization for APM is USD 9.93M.
Unfortunately we do not have enough analyst data on APM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aptorum Group Ltd Class A's stock.
As per our most recent records Aptorum Group Ltd Class A has 3 Employees.
Aptorum Group Ltd Class A's registered address is 17 Hanover Square, London, United Kingdom, W1S 1BN.
You can get more information about it from Aptorum Group Ltd Class A's website at https://www.aptorumgroup.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
